A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

NCT06539208 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Transthyretin Amyloidosis Polyneuropathy
Transthyrexin Amyloidosis Cardiomyopathy

Interventions

DRUG: YOLT-201

Sponsor

YolTech Therapeutics Co., Ltd